Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Evan Ekman

Orthopaedic Surgery Aiken, SC Medical Doctor

NPI 1467400119 CMS profile 292833

191 Centre South Blvd Ste 30, Aiken, SC 29803

Open in the dashboard

General payments

$41,650

30 records reported · program years 2019–2021

Research payments

$6,520

Paid to them · 6 records reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Evan Ekman of Aiken, SC is reported in the CMS Open Payments database as having received $41,650 across 30 general payments and $6,520 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $7,250 2
2021 Research $4,920 3
2020 General $21,417 9
2020 Research $1,600 3
2019 General $12,982 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evan Ekman
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Evan Ekman were reported at $0. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Evan Ekman Orthopaedic Surgery median Middle half National median
2019 $12,982 $644 $140–$2,844 $163
2020 $21,417 $312 $75–$1,860 $114
2021 $7,250 $520 $117–$2,495 $132
2022 $0 $598 $128–$2,731 $149
2023 $0 $461 $128–$2,264 $160
2024 $0 $497 $134–$2,475 $164
2025 $0 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Lilly USA, LLC $20,000 16 payments
  2. Pfizer Inc. $9,159 6 payments
  3. Vertex Pharmaceuticals Incorporated $5,625 2 payments
  4. Eli Lilly and Company $4,800 1 payment
  5. AcelRx Pharmaceuticals, Inc. $2,015 2 payments
  6. Stryker Corporation $20 1 payment
  7. DePuy Synthes Sales Inc. $20 1 payment
  8. Dynasplint Systems Inc. $10 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Consulting Fee $38,305 10 payments
  2. Travel and Lodging $2,035 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $930 2 payments
  4. Food and Beverage $379 14 payments
Products named General payments · program years 2019–2021
  1. DSUVIA $2,015 2 payments
  2. MAKO $20 1 payment
  3. ORTHOVISC $20 1 payment
  4. Dynasplint $10 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2021
  1. Pfizer Inc. $6,520 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

761

Median for Orthopedic Surgery: 203

Drug cost

$9,856

Median for Orthopedic Surgery: $1,433

Branded share of claims

11.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 263 $5,120
Diclofenac Sodium Generic 253 $2,696
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 88 $581
Gabapentin Generic 34 $567
Cephalexin Generic 39 $339
Ibuprofen Generic 29 $264
Mupirocin Generic 26 $201
Meloxicam Generic 13 $75
Diazepam Generic 16 $13

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$111,500

Of which drugs: $3,864

Medicare patients

267

Average age 74

Services billed

1,558

174 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Ischemic heart disease 30%
Depression 26%
Chronic kidney disease 25%
Heart failure 18%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 11 32 $3,021
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 93 596 $422

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record